C36H60Cl2CuN12, monoclinic, P21/c (no. 14), a = 8.3112(2) Å, b = 15.9513(4) Å, c = 17.1068(4) Å, β = 99.671(2)° V = 2235.69(9) Å3, Z = 2, Rgt(F) = 0.0523, wRref(F2) = 0.1606, T = 298(2) K
C80H96N32Cu11Br14, triclinic, P1̄ (no. 2), a = 11.370(2) Å, b = 14.287(3) Å, c = 17.621(3) Å, α = 85...
In the title compound, [Cu(C10H9N2O2)(C10H10N2O2)], the CuI ion is situated at a crystallographic ce...
C46H36Cu2O10, monoclinic, C2/c (no. 15), a = 32.663(7) Å, b = 7.4214(15) Å, c = 21.785(4) Å, β = 131...
C20H24Cu4Cl6N8O, orthorhombic, P212121 (no. 19), a = 12.159(7) Å, b = 14.299(8) Å, c = 19.186(11) Å,...
C6H10N2, triclinic, P1‾$‾{1}$ (no. 2), a = 7.4423(5) Å, b = 7.9420(5) Å, c = 11.6711(8) Å, α ...
C16H13Cl2CuN3O3, monoclinic, P21/c (no. 14), a = 11.2656(9) Å, b = 17.1737(14) Å, c = 8.7774(7) Å, β...
The crystal and molecular structure of the monomeric title compound, chlorotetrakis(2-methylimidazol...
The crystal and molecular structure of the monomeric title compound, chlorotetrakis(2-methylimidazol...
C17H15ClCuN6O2, monoclinic, P121/c1 (No. 14), a = 7.715(3) Å, b = 14.382(2) Å, c = 16.457(3) Å, β = ...
C20H16ClCuN3O4, triclinic, P1̄ (no. 2), a = 7.629(4) Å, b = 8.893(5) Å, c = 14.193(8) Å, α = 88.603(...
The hexanuclear title compound, [{Cu3(μ3-OCH3)(μ-C3H2ClN2)3}2(μ-C3H2ClN2)3(μ6-Cl)] or [Cu6(C3H2ClN2)...
The molecular structure of the title compound, [CuCl(C7H12N2S)2], shows a slightly distorted trigona...
The hexanuclear title compound, [{Cu3(3-OCH3)(-C3H2ClN2)3}2(-C3H2ClN2)3(6-Cl)] or [Cu6(C3H2ClN2)9(C...
The title copper(II) complex, {(C27H37N2)[Cu4(CH3COO)8Cl]·3CH2Cl2}n, is a one-dimensional coordinati...
The hexanuclear title compound, [{Cu3(3-OCH3)(-C3H2ClN2)3}2(-C3H2ClN2)3(6-Cl)] or [Cu6(C3H2ClN2)9(C...
C80H96N32Cu11Br14, triclinic, P1̄ (no. 2), a = 11.370(2) Å, b = 14.287(3) Å, c = 17.621(3) Å, α = 85...
In the title compound, [Cu(C10H9N2O2)(C10H10N2O2)], the CuI ion is situated at a crystallographic ce...
C46H36Cu2O10, monoclinic, C2/c (no. 15), a = 32.663(7) Å, b = 7.4214(15) Å, c = 21.785(4) Å, β = 131...
C20H24Cu4Cl6N8O, orthorhombic, P212121 (no. 19), a = 12.159(7) Å, b = 14.299(8) Å, c = 19.186(11) Å,...
C6H10N2, triclinic, P1‾$‾{1}$ (no. 2), a = 7.4423(5) Å, b = 7.9420(5) Å, c = 11.6711(8) Å, α ...
C16H13Cl2CuN3O3, monoclinic, P21/c (no. 14), a = 11.2656(9) Å, b = 17.1737(14) Å, c = 8.7774(7) Å, β...
The crystal and molecular structure of the monomeric title compound, chlorotetrakis(2-methylimidazol...
The crystal and molecular structure of the monomeric title compound, chlorotetrakis(2-methylimidazol...
C17H15ClCuN6O2, monoclinic, P121/c1 (No. 14), a = 7.715(3) Å, b = 14.382(2) Å, c = 16.457(3) Å, β = ...
C20H16ClCuN3O4, triclinic, P1̄ (no. 2), a = 7.629(4) Å, b = 8.893(5) Å, c = 14.193(8) Å, α = 88.603(...
The hexanuclear title compound, [{Cu3(μ3-OCH3)(μ-C3H2ClN2)3}2(μ-C3H2ClN2)3(μ6-Cl)] or [Cu6(C3H2ClN2)...
The molecular structure of the title compound, [CuCl(C7H12N2S)2], shows a slightly distorted trigona...
The hexanuclear title compound, [{Cu3(3-OCH3)(-C3H2ClN2)3}2(-C3H2ClN2)3(6-Cl)] or [Cu6(C3H2ClN2)9(C...
The title copper(II) complex, {(C27H37N2)[Cu4(CH3COO)8Cl]·3CH2Cl2}n, is a one-dimensional coordinati...
The hexanuclear title compound, [{Cu3(3-OCH3)(-C3H2ClN2)3}2(-C3H2ClN2)3(6-Cl)] or [Cu6(C3H2ClN2)9(C...
C80H96N32Cu11Br14, triclinic, P1̄ (no. 2), a = 11.370(2) Å, b = 14.287(3) Å, c = 17.621(3) Å, α = 85...
In the title compound, [Cu(C10H9N2O2)(C10H10N2O2)], the CuI ion is situated at a crystallographic ce...
C46H36Cu2O10, monoclinic, C2/c (no. 15), a = 32.663(7) Å, b = 7.4214(15) Å, c = 21.785(4) Å, β = 131...
DOI
Add to ORKG